A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are transforming the way therapeutics and materials are discovered. Our differentiated, physics-based computational platform enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at a lower cost, compared to traditional methods. Our software platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. We are applying our computational platform to advance a broad pipeline of drug discovery programs in collaboration with leading biopharmaceutical companies. In addition, we use our computational platform to discover novel molecules for our pipeline of proprietary drug discovery programs, which we are advancing through preclinical and clinical development. Traditional drug discovery and development efforts are complex, lengthy and capital-intensive, and are prone to high failure rates.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 256M | 256M | 208M | 217M | 181M | 138M |
| Net Income | -103M | -103M | -187M | 41M | -149M | -100M |
| EPS | $-1.41 | $-1.41 | $-2.57 | $0.54 | $-2.10 | $-1.42 |
| Free Cash Flow | 12M | 12M | -165M | -150M | -128M | -78M |
| ROIC | -54.3% | -26.3% | -38.6% | 8.2% | -29.7% | -17.0% |
| Gross Margin | 55.7% | 55.7% | 63.6% | 64.9% | 55.8% | 47.6% |
| Debt/Equity | 0.30 | 0.30 | 0.28 | 0.46 | 0.26 | 0.14 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -167M | -167M | -209M | -177M | -147M | -111M |
| Operating Margin | -65.2% | -65.2% | -100.8% | -81.9% | -81.1% | -80.8% |
| ROE | -28.4% | -26.3% | -38.6% | 8.2% | -29.7% | -17.0% |
| Shares Outstanding | 73M | 73M | 73M | 75M | 71M | 71M |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 86M | 108M | 138M | 181M | 217M | 208M | 256M | 256M |
| Gross Margin | 57.4% | 58.7% | 47.6% | 55.8% | 64.9% | 63.6% | 55.7% | 55.7% |
| R&D | 39M | 65M | 91M | 126M | 182M | 202M | 173M | 173M |
| SG&A | 27M | 42M | 64M | 91M | 99M | 100M | 95M | 95M |
| EBIT | -39M | -61M | -111M | -147M | -177M | -209M | -167M | -167M |
| Op. Margin | -45.3% | -56.4% | -80.8% | -81.1% | -81.9% | -100.8% | -65.2% | -65.2% |
| Net Income | -25M | -24M | -100M | -149M | 41M | -187M | -103M | -103M |
| Net Margin | -28.7% | -22.6% | -72.8% | -82.4% | 18.8% | -90.2% | -40.4% | -40.4% |
| Non-Recurring | 0 | 0 | -140K | -19K | -142K | -8K | -20K | -20K |
| Returns on Capital | ||||||||
| ROIC | -24.9% | -9.2% | -17.0% | -29.7% | 8.2% | -38.6% | -26.3% | -54.3% |
| ROE | 29.8% | -9.2% | -17.0% | -29.7% | 8.2% | -38.6% | -26.3% | -28.4% |
| ROA | -15.8% | -5.4% | -13.4% | -20.6% | 5.5% | -23.0% | -13.3% | -14.2% |
| Cash Flow | ||||||||
| Op. Cash Flow | -26M | 17M | -71M | -120M | -137M | -157M | 14M | 14M |
| Free Cash Flow | -28M | 14M | -78M | -128M | -150M | -165M | 12M | 12M |
| Owner Earnings | -32M | 2.6M | -100M | -164M | -190M | -213M | -35M | -35M |
| CapEx | 1.8M | 2.5M | 7.2M | 8.0M | 13M | 7.3M | 1.4M | 1.4M |
| Maint. CapEx | 3.6M | 3.7M | 2.8M | 4.3M | 5.6M | 6.2M | 6.0M | 6.0M |
| Growth CapEx | 0 | 0 | 4.3M | 3.7M | 7.9M | 1.2M | 0 | 0 |
| D&A | 3.6M | 3.7M | 2.8M | 4.3M | 5.6M | 6.2M | 6.0M | 6.0M |
| CapEx/OCF | N/A | 15.1% | N/A | N/A | N/A | N/A | 10.4% | 10.4% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 2.2M | 11M | 26M | 40M | 48M | 50M | 43M | 43M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||
| Net Debt | -71M | -631M | -497M | -335M | N/A | -234M | -286M | -121M |
| Cash & Equiv. | 26M | 202M | 120M | 90M | 155M | 147M | 231M | 231M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 109M |
| Debt/Equity | -0.16 | 0.02 | 0.14 | 0.26 | 0.46 | 0.28 | 0.30 | 0.30 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | -93M | 624M | 557M | 448M | 549M | 421M | 364M | 364M |
| Total Assets | 155M | 746M | 756M | 689M | 803M | 823M | 726M | 726M |
| Total Liabilities | 57M | 122M | 199M | 241M | 254M | 402M | 362M | 362M |
| Intangibles | N/A | N/A | 0 | 587K | 0 | N/A | N/A | N/A |
| Retained Earnings | -105M | -130M | -230M | -379M | -338M | -526M | -629M | -629M |
| Working Capital | 74M | 610M | 534M | 425M | 434M | 443M | 330M | 330M |
| Current Assets | 119M | 683M | 625M | 534M | 568M | 635M | 519M | 519M |
| Current Liabilities | 45M | 73M | 91M | 109M | 134M | 192M | 189M | 189M |
| Per Share Data | ||||||||
| EPS | -4.09 | -0.41 | -1.42 | -2.10 | 0.54 | -2.57 | -1.41 | -1.41 |
| Owner EPS | -5.31 | 0.04 | -1.41 | -2.30 | -2.52 | -2.93 | -0.48 | -0.48 |
| Book Value | -15.54 | 10.46 | 7.88 | 6.30 | 7.27 | 5.79 | 4.97 | 4.97 |
| Cash Flow/Share | -4.34 | 0.28 | -1.00 | -1.68 | -1.81 | -2.16 | 0.19 | -1.33 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 6.0M | 59.7M | 70.7M | 71.0M | 75.4M | 72.8M | 73.2M | 73.2M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | 68.9 | N/A | N/A | -8.4 |
| P/FCF | N/A | 344.3 | N/A | N/A | N/A | N/A | 107.6 | 70.0 |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 7.8 | 4.3 | 2.8 | 5.1 | 3.4 | 3.7 | 2.4 |
| Price/Sales | N/A | 32.4 | 35.0 | 10.6 | 11.0 | 8.0 | 6.0 | 3.4 |
| FCF Yield | N/A | 0.3% | -3.2% | -10.1% | -5.4% | -11.4% | 0.9% | 1.4% |
| Market Cap | N/A | 4.9B | 2.4B | 1.3B | 2.8B | 1.4B | 1.3B | 872M |
| Avg. Price | N/A | 58.79 | 68.33 | 27.02 | 31.56 | 22.76 | 21.08 | 11.91 |
| Year-End Price | N/A | 82.06 | 33.96 | 17.71 | 37.21 | 19.77 | 18.31 | 11.91 |
Schrodinger, Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 57.5%. At current prices, the estimated annualized return to fair value is +2.0%.
Schrodinger, Inc. (SDGR) has a 5-year average return on invested capital (ROIC) of -20.7%. This is below average and may indicate limited pricing power.
Schrodinger, Inc. (SDGR) has a market capitalization of $872M. It is classified as a small-cap stock.
Schrodinger, Inc. (SDGR) does not currently pay a regular dividend.
Schrodinger, Inc. (SDGR) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Schrodinger, Inc. (SDGR) reported annual revenue of $256 million in its most recent fiscal year, based on SEC EDGAR filings.
Schrodinger, Inc. (SDGR) has a net profit margin of -40.4%. The company is currently unprofitable.
Schrodinger, Inc. (SDGR) generated $12 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Schrodinger, Inc. (SDGR) has a debt-to-equity ratio of 0.30. This indicates a conservatively financed balance sheet.
Schrodinger, Inc. (SDGR) reported earnings per share (EPS) of $-1.41 in its most recent fiscal year.
Schrodinger, Inc. (SDGR) has a return on equity (ROE) of -26.3%. A negative ROE may indicate losses or negative equity.
Schrodinger, Inc. (SDGR) has a 5-year average gross margin of 57.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 7 years of financial data for Schrodinger, Inc. (SDGR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Schrodinger, Inc. (SDGR) has a book value per share of $4.97, based on its most recent annual SEC filing.